Drug
SB-509
SB-509 is a pharmaceutical drug with 5 clinical trials. Historical success rate of 100.0%.
Total Trials
5
Max Phase
—
Type
DRUG
Molecule
—
Success Metrics
Clinical Success Rate
100.0%
Based on 5 completed trials
Completion Rate
100%(5/5)
Active Trials
0(0%)
Results Posted
0%(0 trials)
Phase Distribution
Ph phase_2
5
100%
Phase Distribution
0
Early Stage
5
Mid Stage
0
Late Stage
Phase Distribution5 total trials
Phase 2Efficacy & side effects
5(100.0%)
Highest Phase Reached
Phase 2Trial Status & Enrollment
Completion Rate
100.0%
5 of 5 finished
Non-Completion Rate
0.0%
0 ended early
Currently Active
0
trials recruiting
Total Trials
5
all time
Status Distribution
Completed(5)
Detailed Status
Completed5
Development Timeline
Analytics
Development Status
Total Trials
5
Active
0
Success Rate
100.0%
Most Advanced
Phase 2
Trials by Phase
Phase 25 (100.0%)
Trials by Status
completed5100%
Recent Activity
0 active trials
Showing 5 of 5
completedphase_2
Clinical Trial of SB-509 in Subjects With Diabetic Neuropathy
NCT01079325
completedphase_2
Clinical Trial of SB-509 in Subjects With Diabetic Neuropathy
NCT00406458
completedphase_2
Stem Cell Mobilization in Diabetic Neuropathy Subjects Receiving SB-509
NCT00665145
completedphase_2
Clinical Trial of SB-509 in Subjects With Diabetic Neuropathy
NCT00476931
completedphase_2
Clinical Trial of SB-509 in Subjects With Amyotrophic Lateral Sclerosis (ALS)
NCT00748501
Clinical Trials (5)
Showing 5 of 5 trials
NCT01079325Phase 2
Clinical Trial of SB-509 in Subjects With Diabetic Neuropathy
NCT00406458Phase 2
Clinical Trial of SB-509 in Subjects With Diabetic Neuropathy
NCT00665145Phase 2
Stem Cell Mobilization in Diabetic Neuropathy Subjects Receiving SB-509
NCT00476931Phase 2
Clinical Trial of SB-509 in Subjects With Diabetic Neuropathy
NCT00748501Phase 2
Clinical Trial of SB-509 in Subjects With Amyotrophic Lateral Sclerosis (ALS)
All 5 trials loaded
Drug Details
- Intervention Type
- DRUG
- Total Trials
- 5